MEDICUS PHARMA LTD. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
MEDICUS PHARMA LTD. (MDCX) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $419.07 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-12
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $419.07K.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.37M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.70M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.36M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $419.07K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.70M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.36M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $541.87K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $455.18K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $565.99K 10-K · filed 2026-03-25 |
| 2023-12-31 | $335.81K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |